SELLAS Life Sciences CEO Angelos Stergiou joined'Fox & Friends' to discuss how artificial intelligence has positively impacted medicine as his company works to develop a vaccine for leukemia. SELLAS Life Sciences CEO Angelos Stergiou says his company is already on the cusp of a finalized leukemia vaccine, but another game-changer – personalized cancer vaccines – could be on the horizon, thanks to artificial intelligence. "I think it's going to be a revolutionary decade in medicine and in clinical research," he said Thursday on "Fox & Friends." "Where AI comes into play is where it's going to allow us to do things expeditiously, and it's going to be more personalized. In other words, if you have a patient with a cancer, we can then use AI to do a genomic sequencing and, with the results, we can then either create a specific vaccine or treatment, or we can say this specific treatment will work for the patient."